Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oligometastatic Prostate Carcinoma: early-phase trial registry
5 of 7 indexed Oligometastatic Prostate Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Oligometastatic Prostate Carcinoma: 7 US clinical trials tracked, 5 recruiting.
Oligometastatic Prostate Carcinoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 4 of these trials.
Enrollment posture brief
Registry condition oligometastatic-prostate-carcinoma
OPEN 5 | RECR 71% | LATE 1 | EARLY 4 | RANK #2497 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)
Oligometastatic Prostate Carcinoma lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oligometastatic Prostate Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oligometastatic Prostate Carcinoma is recruiting above its size-band peers.
5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Oligometastatic Prostate Carcinoma research.
Mayo Clinic accounts for 4 of 7 trials (57.1%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Oligometastatic Prostate Carcinoma enrolment sits around 110 participants.
Median target enrolment is 110 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Oligometastatic Prostate Carcinoma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
NCT05053152
Addressing Health Literacy With a Tailored Survivorship Care Plan
Emory University
NCT06674863
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
NCT06205316
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Mayo Clinic
NCT06369610
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Mayo Clinic
NCT06389786
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
Jonsson Comprehensive Cancer Center
NCT05496959
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
NCT04190446
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Oligometastatic Prostate Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oligometastatic Prostate Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oligometastatic Prostate Carcinoma page
7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Oligometastatic Prostate Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Oligometastatic Prostate Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oligometastatic Prostate Carcinoma condition card totals 7 registered trials; most-linked intervention Computed Tomography; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.